MarketPeel
Insider Trading Intelligence
ES

Eddie Joe Sullivan

SABS
CHIEF EXECUTIVE OFFICER · SAB BIOTHERAPEUTICS, INC. · CIK 0001889712
FILING MIX · LIFETIME100%/0%
BUYS
17
SELLS
0
TOTAL VALUE
$40.0K
COMPANIES
1
ACTIVE SINCE
Oct 2021
HOLDINGS NOW
3,000,000
AVG SELL PX
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Eddie Joe Sullivan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%-4.69%+1.10%-5.79%-5.79%
14d2+50.00%-8.14%-0.58%-7.56%-7.56%
30d2+50.00%+4.72%-2.95%+7.67%+7.67%
60d2+50.00%+7.50%+1.92%+5.58%+5.58%
90d2+50.00%+6.88%+5.55%+1.32%+1.32%
180d2+0.00%-39.33%+9.35%-48.68%-48.68%
1y2+50.00%-32.05%+24.05%-56.10%-56.10%
2y2+0.00%-56.74%+46.31%-103.05%-103.05%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SABS · 3,000,000 shares · as of Feb 3, 2026
01,308,0762,616,1523,924,2285,232,30420222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 17 buys / 0 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,000,0003,000,000Feb 3, 2026Feb 5, 2026View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,000,0003,000,000Aug 26, 2025Aug 28, 2025View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,4474,447Jul 15, 2024Jul 17, 2024View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
46,52846,528Jul 15, 2024Jul 17, 2024View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
190,000190,000Feb 21, 2024Feb 23, 2024View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
1,740$0.88$1.5K5,232,304Dec 7, 2023Dec 8, 2023View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
525,000525,000Mar 14, 2023Mar 16, 2023View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,00035,000Sep 13, 2022Sep 15, 2022View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
14,000$0.74$10.3K5,230,564Sep 7, 2022Sep 8, 2022View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,21821,218Mar 16, 2022Mar 18, 2022View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
162,850162,850Oct 22, 2021Oct 26, 2021View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,26423,264Oct 22, 2021Oct 26, 2021View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
139,585139,585Oct 22, 2021Oct 26, 2021View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,213,7645,213,764Oct 22, 2021Oct 26, 2021View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,106,3612,106,361Oct 22, 2021Oct 26, 2021View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
197,374197,374Oct 22, 2021Oct 26, 2021View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,800$10.07$28.2K2,800Oct 7, 2021Oct 26, 2021View →
Other insiders · SABS
Loading peer insiders…
About this filer
CIK 0001889712
ROLE
CHIEF EXECUTIVE OFFICER
PRIMARY
SABS
COMPANIES
1
ACTIVE SINCE
Oct 2021
MARKETPEEL · /INSIDER/0001889712DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback